Psychedelics and Psychedelic-Assisted Psychotherapy.

  title={Psychedelics and Psychedelic-Assisted Psychotherapy.},
  author={Collin M Reiff and Elon E. Richman and Charles B. Nemeroff and Linda L. Carpenter and Alik S. Widge and Carolyn I. Rodriguez and Ned H. Kalin and William M. McDonald},
  journal={The American journal of psychiatry},
OBJECTIVE The authors provide an evidenced-based summary of the literature on the clinical application of psychedelic drugs in psychiatric disorders. METHODS Searches of PubMed and PsycINFO via Ovid were conducted for articles in English, in peer-reviewed journals, reporting on "psilocybin," "lysergic acid diethylamide," "LSD," "ayahuasca," "3,4-methylenedioxymethamphetamine," and "MDMA," in human subjects, published between 2007 and July 1, 2019. A total of 1,603 articles were identified and… 

Figures and Tables from this paper

Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm
The sum of this research points towards medicinal psychedelics as a potential new class of psychiatric treatments when used within a medically supervised framework with integrated psychotherapeutic support, but before widespread translation into clinical use can occur, appropriately designed and sufficiently powered trials are required to detect both potential positive and negative outcomes.
Are Psychedelics Something New in Teaching Psychopharmacology?
This editorial focuses on teaching residents about these fascinating and ancient compounds called psychedelics, because they present an opportunity to educate the authors' residents regarding aspects of the scientific method.
The Potential Role of Serotonergic Hallucinogens in Depression Treatment
The reviewed studies suggest that psychedelics have great potential in depression therapy and, after addressing and overcoming the current study limitations, may be used as a novel method of treating depression in the future.
Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis
The effects of psilocybin, ayahuasca, and lysergic acid diethylamide (LSD) on psychological outcomes in the post-acute period are quantified and test moderators of these effects are evaluated; adverse effects and risk of bias are evaluated.
Can the revival of serotonergic psychedelic drugs as treatments for mental disorders help to characterize their risks and benefits?
Classic psychedelics are a loosely grouped class of drugs that activate serotonin 5HT2A receptors to induce complex behavioral, psychological, and physiological effects [1]; 5HT2A agonism induces the
Motives for the use of serotonergic psychedelics: A systematic review.
ISSUES Serotonergic psychedelics (SP) are psychoactive substances that produce unique sets of subjective effects, such as hallucinatory experiences. This systematic review is the first to summarise
The Role of Psychedelics in Managing Anxiety, Depression, and Flashbacks of Individuals with Post-Traumatic Stress Disorder
Findings indicate a therapeutic effect on patients with PTSD when using psilocybin, and the medical community should take steps toward novelty treatments for psychiatric diagnoses.
The Need for Psychedelic-Assisted Therapy in the Black Community and the Burdens of Its Provision
Psychedelic medicine is an emerging field that examines entheogens, psychoactive substances that produce non-ordinary states of consciousness (NOSC). 3,4-methylenedioxymethamphetamine (MDMA) is
Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Systematic Review of Published Case Studies
There is some evidence of risk of activating mania with these substances, but that the risk does not appear to be strong or overwhelming, and a careful prospective study appears warranted in this population.


The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging
Acute, subacute, and long-term AYA use seems to have low toxicity, and preliminary studies about potential therapeutic effects of AYA need replication due to their methodological limitations.
Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions
An overview of past and present models of psychedelic therapy is provided, and important considerations for future interventions incorporating the use of psychedelics in research and clinical practice are discussed.
Therapeutic Applications of Classic Hallucinogens.
This chapter reviews what is known about the therapeutic uses of the serotonergic or classic hallucinogens, i.e., psychoactive drugs such as LSD and psilocybin that exert their effects primarily
Positive psychology in the investigation of psychedelics and entactogens: A critical review
The influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training
Clinical research on psychedelic-assisted psychotherapy is rapidly advancing in the USA, with two drugs, psilocybin and MDMA, progressing through a structure of FDA-approved trials on a trajectory
Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects.
The short-term administration of MDMA produced marked euphoria, a slight impairment in the performance of psychomotor tasks, and mild changes in body perceptions without hallucinations, which support the abuse liability of MDMA.
A review of lysergic acid diethylamide (LSD) in the treatment of addictions: historical perspectives and future prospects.
It is concluded that further research into LSD's potential as a treatment for addictions is warranted.
The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.
  • H. Kalant
  • Medicine, Psychology
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
  • 2001
The available evidence does not yet permit an accurate assessment of the size of the problem presented by the use of these drugs, but a detailed review of the literature has revealed over 87 "ecstasy"-related fatalities.
Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies
Individuals with a personal or family history of any psychotic illness or nonpsychotic mania should avoid hallucinogen intake.